"MPTP Poisoning" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition caused by the neurotoxin MPTP which causes selective destruction of nigrostriatal dopaminergic neurons. Clinical features include irreversible parkinsonian signs including rigidity and bradykinesia (PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al., Principles of Neurology, 6th ed, p1072; Neurology 1986 Feb;36(2):250-8)
Descriptor ID |
D020267
|
MeSH Number(s) |
C10.228.140.079.862.800.300 C10.228.662.600.700.250 C10.720.606 C25.723.705.400
|
Concept/Terms |
MPTP Poisoning- MPTP Poisoning
- Poisoning, MPTP
- Neurotoxicity Syndrome, MPTP
- MPTP-Induced Parkinsonism
- MPTP Induced Parkinsonism
- Parkinsonism, MPTP-Induced
- Poisoning, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- MPTP Neurotoxicity Syndrome
- MPTP Neurotoxicity Syndromes
- Neurotoxicity Syndromes, MPTP
|
Below are MeSH descriptors whose meaning is more general than "MPTP Poisoning".
Below are MeSH descriptors whose meaning is more specific than "MPTP Poisoning".
This graph shows the total number of publications written about "MPTP Poisoning" by people in this website by year, and whether "MPTP Poisoning" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 |
2005 | 0 | 1 | 1 |
2006 | 1 | 0 | 1 |
2009 | 1 | 0 | 1 |
2012 | 2 | 0 | 2 |
2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "MPTP Poisoning" by people in Profiles.
-
Smeyne M, Sladen P, Jiao Y, Dragatsis I, Smeyne RJ. HIF1a is necessary for exercise-induced neuroprotection while HIF2a is needed for dopaminergic neuron survival in the substantia nigra pars compacta. Neuroscience. 2015 Jun 04; 295:23-38.
-
Adeosun SO, Hou X, Jiao Y, Zheng B, Henry S, Hill R, He Z, Pani A, Kyle P, Ou X, Mosley T, Farley JM, Stockmeier C, Paul I, Bigler S, Brinton RD, Smeyne R, Wang JM. Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease. PLoS One. 2012; 7(11):e50040.
-
Gerecke KM, Jiao Y, Pagala V, Smeyne RJ. Exercise does not protect against MPTP-induced neurotoxicity in BDNF haploinsufficient mice. PLoS One. 2012; 7(8):e43250.
-
Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2933-8.
-
Anderson DW, Bradbury KA, Schneider JS. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci. 2006 Dec; 24(11):3174-82.
-
Faherty CJ, Raviie Shepherd K, Herasimtschuk A, Smeyne RJ. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Brain Res Mol Brain Res. 2005 Mar 24; 134(1):170-9.
-
Hamre K, Tharp R, Poon K, Xiong X, Smeyne RJ. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res. 1999 May 15; 828(1-2):91-103.